AnaptysBio
ANAB
116 hedge funds and large institutions have $615M invested in AnaptysBio in 2023 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 38 increasing their positions, 35 reducing their positions, and 11 closing their positions.
27% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 11
2.99% more ownership
Funds ownership: 111.13% → 114.12% (+3%)
3% more funds holding
Funds holding: 113 → 116 (+3)
9% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 35
2% more call options, than puts
Call options by funds: $1.2M | Put options by funds: $1.18M
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
9% less capital invested
Capital invested by funds: $675M → $615M (-$60.4M)
Top Buyers
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$11.7M |
| 2 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$6.53M |
| 3 |
B
Braidwell
Stamford,
Connecticut
|
+$3.68M |
| 4 |
Millennium Management
New York
|
+$2.78M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$1.82M |
Top Sellers
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$26.4M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$4.76M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.49M |
| 4 |
JP Morgan Chase
New York
|
-$3.78M |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$2.64M |
ANAB Hedge Fund Activity: Q2 2023 in Review
116 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in AnaptysBio (ANAB) for Q2 2023, worth a combined $615M — down 8.9% from $675M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new ANAB positions and 11 closed out — a net gain of 3 holders — while 38 added to existing stakes and 35 trimmed.
The largest buyer was Woodline Partners, adding an estimated $11.7M. The largest seller was Federated Hermes, cutting an estimated $26.4M.
- 116 institutional investors held AnaptysBio (ANAB) as of Q2 2023, up from 113 in Q1 2023.
- Funds reported $615M of AnaptysBio stock for Q2 2023, down 8.9% quarter-over-quarter.
- 14 funds opened new AnaptysBio positions in Q2 2023 and 11 closed out, a net change of +3 holders.
- The largest AnaptysBio buyer in Q2 2023 was Woodline Partners, an estimated $11.7M added.
- The largest AnaptysBio seller in Q2 2023 was Federated Hermes, an estimated $26.4M sold.
Based on aggregated 13F filings for Q2 2023.